| Management target | Revenue 50.0% FY27 |
|---|
| Revenue growth | FY27 growth guided >50%; mid-term CAGR 20-25%. |
|---|---|
| Margins | Improving; driven by high-margin Ethical (76% GM) and Own-Brands. |
| Demand visibility | Strong; fueled by commercialized CDMO partnerships and new registrations. |
| Management confidence | High; citing clear momentum and structural transformation. |
Growth
Standalone Q1FY27 Revenue up 21.16% YoY to ₹186.08 Cr. Operating EBITDA surged 2.85x to ₹33.32 Cr; margins expanded 1,258 bps to 17.91%.
Outlook
Guided FY27 revenue growth over 50%. Mid-term revenue CAGR of 20-25% with 600-800 bps EBITDA margin expansion.
Risks
Regulatory compliance across 85+ countries and execution risks in scaling new CDMO partnerships.
Investor Presentation filed with BSE, NSE: INDSWFTLAB. Summary written with AI assistance from the document.
Ind-Swift Laboratories Ltd: key numbers
- Share price
- ₹404.35
- Market cap
- ₹3,516 Cr
- Revenue (annual)
- ₹641.3 Cr
- Net profit (annual)
- ₹41.42 Cr
- P/E (TTM)
- 61.3×Sector 50.4×
- Promoter holding
- 42.93%-0.06% QoQ
- FII holding
- 10.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ind-Swift Laboratories Ltd
All →Ind-Swift Laboratories Other Announcement
Ind-Swift Laboratories Ltd has filed its quarterly shareholding pattern as mandated by Regulation 31(1)(c) of the SEBI Listing Regulations.
Ind-Swift Laboratories Capital Structure Change
Promoter entity Essix Biosciences Limited acquired 70,00,000 fully convertible warrants of Ind-Swift Laboratories via a preferential allotment.
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories allotted 70 lakh fully convertible warrants at Rs. 196 each, totaling Rs. 137.2 Crore. This preferential issue will augment capital upon warrant conversion.
- Value
- ₹137.2 Cr
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories Limited allotted 70,00,000 fully convertible warrants to Essix Biosciences Limited on a preferential basis. The company received Rs. 34.30 Crore as upfront payment.
- Value
- ₹34.30 Cr
Ind-Swift Laboratories Annual Report
Ind-Swift Laboratories has submitted its Annual Report for the financial year 2025-26. This filing provides the company's detailed financial performance and operational updates.
Ind-Swift Laboratories Annual General Meeting
Ind-Swift Laboratories Ltd will hold its 31st Annual General Meeting on September 30, 2026, via video conference. The agenda includes financial adoption and director appointments.